melevodopa and decarboxylase inhibitor

N04BA05

Forms & Strengths

Melevodopa combined with a peripheral decarboxylase inhibitor (e.g., carbidopa or benserazide) in various fixed-dose oral tablet formulations.

Adult Dosing

Individualized titration based on clinical response and tolerability.
Initial dose typically established by substituting for previous levodopa/decarboxylase inhibitor therapy at calculated equivalent melevodopa ratios.
Administered orally, frequently divided into multiple daily doses.

Pediatric Dosing

Safety and efficacy in pediatric patients have not been established; use in children is generally not recommended.

Indications

Treatment of Parkinson's disease and related syndromes to manage motor symptoms such as bradykinesia, rigidity, and tremor.

Mechanism of Action

Melevodopa is a water-soluble methyl ester prodrug of levodopa that is rapidly converted to levodopa in the body.
Levodopa crosses the blood-brain barrier and is decarboxylated to dopamine in the central nervous system to replenish depleted striatal dopamine.
Co-administration with a peripheral decarboxylase inhibitor prevents peripheral metabolism of levodopa, increasing its bioavailability in the central nervous system and reducing peripheral adverse effects.

Contraindications

Hypersensitivity to melevodopa, levodopa, or any component of the formulation.
Concurrent use of non-selective monoamine oxidase (MAO) inhibitors due to the risk of hypertensive crisis.
Narrow-angle glaucoma.
Suspicious undiagnosed skin lesions or a history of melanoma.

Adverse Reactions

Dyskinesias and choreiform movements
Nausea, vomiting, and anorexia
Orthostatic hypotension and dizziness
Psychiatric disturbances including confusion, hallucinations, depression, and psychosis
Somnolence and sudden onset of sleep

Drug Interactions

Non-selective MAO inhibitors: risk of severe hypertension.
Antipsychotics and dopamine antagonists: may antagonize the therapeutic anti-Parkinsonian effects of levodopa.
Antihypertensives: potential for additive orthostatic hypotension.
Iron salts: may chelate levodopa and reduce its gastrointestinal absorption.

Curated Content: Needs Vetting Before Put to Clinical Use